Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma

Abstract

A decision analytic model was constructed to assess the cost–effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost–effectiveness than the conventional therapies. Survival outcomes, quality of life of progression-free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost–effectiveness of O-B-O. The cost–effectiveness proportions of O-B-O relative to conventional therapies under the recommended cost–effectiveness threshold ranged from 61.0% to 99.9%. Thus, O-B-O was highly cost-effective for treating patients with rrFL in China compared with conventional therapies.